Your browser does not support iframes.
During their visit, the guests attended a lecture about Teva and its position in the Israeli and global industry, and took a tour of the tablet factory in Kfar Saba.The Teva-Handok business venture was launched in February 2013. Teva contributes its global resources, with responsibilities for manufacturing and supplying a wide range of affordable and innovative medicines. Handok’s primary responsibility are in sales and marketing, distribution, and regulatory affairs. Teva has a controlling stake in the business venture, with a profit split of 51% for Teva and 49% for Handok.For more details on Teva’s South Korea venture >>
For the press release on the South Korea venture >>